Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

B. Gilbert, Peter; C. Montefiori, David; B. McDermott, Adrian; Fong, Youyi; Benkeser, David; Deng, Weiping; Zhou, Honghong; R. Houchens, Christopher; Martins, Karen; Jayashankar, Lakshmi; Castellino, Flora; Flach, Britta; C. Lin, Bob; O’Connell, Sarah; McDanal, Charlene; Eaton, Amanda; Sarzotti‐Kelsoe, Marcella; Lu, Yiwen; Yu, Chenchen; Borate, Bhavesh; W. P. van der Laan, Lars; S. Hejazi, Nima; Huynh, Chuong; M. Miller, Jacqueline; M. El Sahly, Hana; R. Baden, Lindsey; Baron, Mira; de la Cruz‐Merino, Luis; L. Gay, Cynthia; A. Kalams, Spyros; F. Kelley, Colleen; P. Andrasik, Michele; G. Kublin, James; Corey, Lawrence; M. Neuzil, Kathleen; N. Carpp, Lindsay; Pajón, Rolando; Follmann, Dean; O. Donis, Rubén; A. Koup, Richard; Assays Team§, Immune; Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§, Coronavirus; States Government (USG)/CoVPN Biostatistics Team§, United

doi:10.1126/science.abm3425

Public

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Published in Science • Jan 6, 2022

Authors:

Peter B. Gilbert

David C. Montefiori

Adrian B. McDermott

Abstract

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with...

Subject

Antibody

Immunology

Vaccine efficacy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!